Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNCHRO: how erenumab modulates chronic migraine
2019-002224-32Phase 4Completed
- Sponsor
- Vall d'Hebron Research Institute
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of erenumab in chronic migraine (2 arms), sponsored by Vall d'Hebron Research Institute. Primary endpoint: MRI morphometric and structural connectivity changes after erenumab. Started Jul 2019; status: completed.
02
Drugs
erenumab
03
Conditions
chronic migraine
Beyond the preview
Go deeper on 2019-002224-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002224-32.